New Partnership Announced
Venture Philanthropy
Prosensa is developing an exon skipping compound that looks promising.
CureDuchenne is proud to announce our partnership with Prosensa, a Dutch biotech company dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics.
After months of investigation, CureDuchenne has determined that Prosensa has one of the most promising therapies for Duchenne. CureDuchenne will hold Prosensa accountable for results, and funding is predicated upon success at each milestone.
In order to move the trial process forward, CureDuchenne has committed to $1.4 million over the next year. We need your help to make sure that this potential lifesaving research moves forward quickly. Two boys die of Duchenne Muscular Dystrophy every day.
Your donation will go directly to fund this research. Please help us save our son and the thousands of other young boys afflicted with this condition.
|